

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 37 years Female

Specimen Collected: 21-Jun-22 15:39

Epidermal Transglutaminase Ab IgA, ELISA		Received: 22-Jun-22 10:02	Report/Verified: 22-Jun-22 10:10
---	--	----------------------------------	---

Procedure	Result	Units	Reference Interval
EER Epidermal Transglutaminase Ab, IgA	See Note ^{f1}		

Epidermal Transglutaminase Ab IgA, ELISA		Received: 22-Jun-22 09:57	Report/Verified: 22-Jun-22 12:04
---	--	----------------------------------	---

Procedure	Result	Units	Reference Interval
Epidermal Transglutaminase Ab IgA, ELISA	See Note ^{f2}		

Result Footnote

f1: EER Epidermal Transglutaminase Ab, IgA
Authorized individuals can access the ARUP
Enhanced Report using the following link:

f2: Epidermal Transglutaminase Ab IgA, ELISA
CLINICAL INFORMATION
Skin lesions and gastrointestinal symptoms. Presumptive diagnosis is dermatitis herpetiformis.

Specimen Details
S22-IP0000500 - Serum; Collected: 6/21/2022; Received: 6/22/2022

DIAGNOSTIC INTERPRETATION

Increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level by ELISA, providing support for the diagnosis of dermatitis herpetiformis

(See Results and Comments)

RESULTS

Enzyme-Linked Immunosorbent Assay (ELISA)

Epidermal Transglutaminase (eTG/TG3) IgA Antibodies

IgA epidermal transglutaminase antibody level: 55 U/mL (H)

Reference Range:

Normal (negative) = Less than 16 U/mL
Borderline/Indeterminate = 16-22 U/mL
Increased (H) (positive) = Greater than 22 U/mL

COMMENTS

Specific

This ELISA result, demonstrating an increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level, supports the diagnosis of dermatitis herpetiformis. Most patients with dermatitis herpetiformis have associated celiac disease.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 22-172-118659

Report Request ID: 16631964

Printed: 16-Sep-22 09:53

Page 1 of 2

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 37 years Female

Result Footnote

f2: Epidermal Transglutaminase Ab IgA, ELISA
 Clinical correlation is needed including with direct immunofluorescence findings on a biopsy specimen and assessment of celiac disease serologies, including serum IgA endomysial antibodies by indirect immunofluorescence and IgA tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), antibodies by ELISA. If not already performed, direct immunofluorescence testing can be accomplished on a biopsy specimen submitted through ARUP Laboratories [ARUP test number 0092572, Direct Immunofluorescence, Tissue Biopsy (Cutaneous, Mucosal, Epithelial)], and testing for serum celiac disease antibodies may be accomplished by request (ARUP test number 2008114, Celiac Disease Reflexive Cascade); contact ARUP Client Services, 1-800-242-2787, option 2, for assistance.

IgA eTG/TG3 antibody levels correlate with disease activity in individual patients with dermatitis herpetiformis; therefore, monitoring antibody levels may aid in assessing disease activity, including as related to gluten ingestion.

General

Epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), is the dominant antigen to which IgA antibodies develop in dermatitis herpetiformis. IgA epidermal transglutaminase antibodies account for the characteristic dermal IgA reactivity (subepithelial granules or fibrils beneath the basement membrane zone with stippling in dermal papillae) observed by direct immunofluorescence in skin biopsy specimens. An increased IgA eTG/TG3 antibody level in serum is distinctly characteristic of dermatitis herpetiformis.

Levels of IgA eTG/TG3 antibodies may correlate with disease activity in individual patients with dermatitis herpetiformis. Most patients with dermatitis herpetiformis have gluten sensitivity with celiac disease and characteristic IgA antibodies to tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), by ELISA, along with positive IgA endomysial antibodies by indirect immunofluorescence which correlate with disease activity. Patients with dermatitis herpetiformis can have an antibody profile specific for eTG/TG3 with higher avidity than to tTG/TG2; however, a normal IgA eTG/TG3 antibody level does not rule out the diagnosis of dermatitis herpetiformis.

TESTING METHODSEnzyme-Linked Immunosorbent Assay (ELISA)

IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level in serum determined by ELISA (ALPCO Immunoassays). The performance characteristics of this ELISA testing were determined by the Immunodermatology Laboratory at the University of Utah. The testing has not been cleared or approved by the FDA (US Food and Drug Administration). FDA clearance or approval currently is not required for this testing performed in a CLIA-certified laboratory (Clinical Laboratory Improvement Amendments) and intended for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. [One ELISA]

Electronically signed by Kristin M. Leiferman, MD, on 06/22/22 at 12:02 PM.

Performed At: IMMUNODERMATOLOGY LABORATORY

417 S. WAKARA WAY, SUITE 2151

SALT LAKE CITY, UT 84108

Medical Director: JOHN JOSEPH ZONE, MD

CLIA Number: 46D0681916

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab-----
Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 22-172-118659**Report Request ID:** 16631964**Printed:** 16-Sep-22 09:53

Page 2 of 2